Kura Oncology (NASDAQ:KURA) Receives Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Kura Oncology (NASDAQ:KURA) in a research note issued to investors on Thursday,Benzinga reports.

Several other research analysts have also recently commented on KURA. Stifel Nicolaus cut Kura Oncology from a “buy” rating to a “hold” rating and lowered their target price for the stock from $26.00 to $19.00 in a research note on Monday, October 14th. StockNews.com downgraded Kura Oncology from a “hold” rating to a “sell” rating in a research report on Wednesday. HC Wainwright raised their target price on shares of Kura Oncology from $32.00 to $37.00 and gave the company a “buy” rating in a report on Thursday. Lifesci Capital upgraded shares of Kura Oncology to a “strong-buy” rating in a research note on Tuesday, October 22nd. Finally, UBS Group started coverage on shares of Kura Oncology in a research report on Thursday, October 24th. They issued a “buy” rating and a $27.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Kura Oncology presently has a consensus rating of “Moderate Buy” and an average target price of $29.38.

Kura Oncology Stock Up 9.1 %

Shares of NASDAQ:KURA traded up $0.92 during trading on Thursday, hitting $10.98. The company’s stock had a trading volume of 2,521,641 shares, compared to its average volume of 974,485. Kura Oncology has a fifty-two week low of $9.06 and a fifty-two week high of $24.17. The business has a 50 day moving average price of $18.28 and a two-hundred day moving average price of $19.82. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. The company has a market capitalization of $853.85 million, a PE ratio of -4.63 and a beta of 0.86.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. nVerses Capital LLC acquired a new stake in Kura Oncology during the 3rd quarter worth $25,000. SG Americas Securities LLC purchased a new position in shares of Kura Oncology during the first quarter worth about $110,000. Point72 DIFC Ltd purchased a new position in shares of Kura Oncology during the third quarter worth about $146,000. Quarry LP acquired a new stake in shares of Kura Oncology during the second quarter worth about $196,000. Finally, Erste Asset Management GmbH purchased a new stake in shares of Kura Oncology in the 3rd quarter valued at about $215,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.